This study aimed to determine the pharmacokinetics, pharmacodynamics, safety, and tolerability of brensocatib in adults with cystic fibrosis treated with or without cystic fibrosis transmembrane conductance regulator modulators. This evidence concerns the gene CFTR and cystic fibrosis.